diazoxide


Also found in: Thesaurus, Medical, Wikipedia.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.diazoxide - vasodilator (trade name Hyperstat) used to treat severe hypertension
vasodilative, vasodilator - a drug that causes dilation of blood vessels
References in periodicals archive ?
'We are pleased with the progress in our ongoing Phase III clinical trial, DESTINY PWS, evaluating once-daily Diazoxide Choline Controlled-Release (DCCR) tablets for patients with Prader Willi Syndrome (PWS).
Soleno Therapeutics provided an update on the Company's ongoing Phase III trial, DESTINY PWS, evaluating once-daily Diazoxide Choline Controlled-Release tablets for patients with Prader-Willi Syndrome/ As of July 24, 2019, approximately 50% of the targeted number of patients have been enrolled into the DESTINY PWS clinical study and more than 90% of those patients have either successfully completed or continue to be treated on study.
The potentiated effect of obestatin was believed to be lost in presence of diazoxide which activated the ATP sensitive K + channels reflecting their sensitivity of these channels to obestatin12.
She had been treated by diazoxide for 10 months in a dose of 10 mg/kg/d with a 5% maltose dextrin diet, under correct glycaemic monitoring.
Prior to this, diazoxide choline received orphan designation for the treatment of PWS in the US and in the E.U.
She had a diagnosis of transient hyperinsulinemic hypoglycemia (serum insulin 20 IU/mL, glucose 34 mg/dL) during the neonatal and early infancy period and had been on diazoxide therapy.
Soleno Therapeutics was granted Fast Track designation by the FDA to Diazoxide Choline Controlled-Release (DCCR) for the treatment of Prader-Willi Syndrome (PWS).
Soleno Therapeutics Inc (NASDAQ: SLNO) has launched its Phase III clinical trial of Diazoxide Choline Controlled-Release (DCCR) for the treatment of Prader-Willi Syndrome (PWS), the biopharmaceutical company revealed on Monday.
Riazuddin, "Diazoxide preconditioning of endothelial progenitor cells from streptozotocin-induced type 1 diabetic rats improves their ability to repair diabetic cardiomyopathy," Molecular and Cellular Biochemistry, vol.
Medical management of GDH-HI disease relies on protein restriction and/or treatment with diazoxide. More than 100 patients with GDH-HI have been described [4].
Fifty-five (70%) of the patients used preoperative medication: 47 (59%) used diazoxide, 10 (13%) used a somatostatin analogue, and 4 (5%) used both compounds.